|
NEWS@IQ
|
|
|
|
|
In this newsletter we are happy to announce:
Ø New product: IQ Perm, erythrocyte permeabilization buffer
Ø Publication on clinical presentation of patients with adverse
effects towards AstraZeneca vaccine using the HITAlert™
Ø Webinar on consquences of the European IVDR regulation on 15th
of June: What will change for
manufacturers, distributors and diagnostic laboratories?
Ø Publication from our Research and Development department on Circulating Guanylate-Binding-Protein-1
(GBP-1) in healthy and
preeclamptic women
|
|
|
|
New product
IQ Perm, erythrocyte
permeabilization buffer
|
|
|
This buffer can be used in combination with our anti-hemoglobin
antibodies, such as anti-hemoglobin S, anti-hemoglobin F, and anti-panHb
(HbA alpha chain), conjugated with various
fluorochromes.
IQ Perm is used to permeabilize cells
prior to intracellular staining of erythrocytes, but is also suitable for
permeabilization of leukocytes. It should be applied to fixed cells prior
to antibody staining, followed by flow cytometric analysis.
|
|
|
|
|
Publication HITAlert™
|
|
|
In rare cases, adverse
reactions are observed following vaccination with the AstraZeneca vaccine
(Vaxzevria). The vaccine induced thrombosis and thrombocytopenia (VITT)
resembles the symptoms of heparin induced thrombocytopenia (HIT).
Therefore, several countries recommend to follow the screening procedure
for HIT when this adverse reaction to the vaccine is observed.
The UCLH just published a study in which they aim to gain a better understanding of the
described clinical syndrome of VITT. For this purpose, they used the
diagnostic screening procedure of HIT, including assessment of antibodies
using ELISA and a functional assay, in this case IQ Products’ HITAlertTM kit.
Visit our website page here for more information about the HITAlertTM kit.
|
|
|
|
|
Webinar on IVDR: 15th of June
|
|
|
The new Regulation
(EU) 2017/746 on In Vitro Diagnostic Medical Devices Regulation (IVDR)
will become effective in Europe on 26th
of May 2022. The IVDR will replace the current Directive 98/79/EC (IVDD)
and has major impact on all companies and institutes dealing with IVD CE
products.
The full IVDR requirements
are extensive, therefore, we will organize a webinar providing an
overview of the key points of the new regulation and an opportunity for a
discussion on the implementation.
The webinar will
take place on the 15th of June. We
have reserved 2 time slots: 10:00h and 16:00h Central European time (CET).
If you would like to participate in the webinar, please send an email to marketing@iqproducts.nl to receive an invitation.
|
|
|
|
|
Publication from our R&D department
|
|
|
Our R&D
department studies early biomarkers during pregnancy to assess the risk
for pregnancy related disorders, in this case pre-eclampsia. The results
of one of their studies have just been published!
In this study, they looked
at Guanylate-Binding-Protein-1 (GBP-1) in peripheral blood during healthy
and preeclamptic pregnancies. The publication describes that plasma GBP-1
levels do not increase in early or late onset pre-eclamptic pregnancies,
while it increases during healthy pregnancies as compared to non-pregnant
women.
Do you want to learn
more? Check out the full paper here
|
|
|
|
|
Upcoming events 2021*
|
|
|
Sept 2021 - AACC, Atlanta, Georgia, USA
Nov 2021 -
NVC/NVKC, Zwolle, The Netherlands
*Unfortunately,
many organizations have been forced to cancel or postpone their events.
As soon as we have more information on new dates, they will be posted on
our website.
|
|
|
|
|
Thank you for your interest in IQ Products!
|
|
|
|
Address details
Rozenburglaan 13a
9727 DL Groningen
Netherlands
Technical
questions:
tech@iqproducts.nl
Marketing:
marketing@iqproducts.nl
www.iqproducts.nl
|
How to order at IQ Products:
By
e-mail:
orders@iqproducts.nl
By
fax:
+31
(0)50 57 57 002
By
phone:
+31
(0)50 57 57 000
Find your local distributor online:
www.iqproducts.nl/company/distributors/
|
Follow us:
 @iqproducts.nl
 linkedin.com/company
/iq-products
|
|
|
|
|
|
|
|
|
